These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
52 related articles for article (PubMed ID: 2581243)
1. Glycosylated proteins in diabetic nephropathy. Ramzy M; Habib M; el-Sheemy N; Dunn M; Iskander I; Samney S; Doss SH Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():649-54. PubMed ID: 2581243 [TBL] [Abstract][Full Text] [Related]
2. [Serum beta 2 microglobulin assay in diabetes mellitus (author's transl)]. Schlienger JL; Reiss D; Anceau A; Simon C; Stephan F Sem Hop; 1982 Apr; 58(16):959-62. PubMed ID: 6178166 [TBL] [Abstract][Full Text] [Related]
3. Cystatin C is not more sensitive than creatinine for detecting early renal impairment in patients with diabetes. Oddoze C; Morange S; Portugal H; Berland Y; Dussol B Am J Kidney Dis; 2001 Aug; 38(2):310-6. PubMed ID: 11479157 [TBL] [Abstract][Full Text] [Related]
4. [A study on inactive renin in the plasma of patients with diabetes mellitus]. Yoshida H Hokkaido Igaku Zasshi; 1989 May; 64(3):232-42. PubMed ID: 2670725 [TBL] [Abstract][Full Text] [Related]
5. [Plasma and urine beta-thromboglobulin determination in the detection of thrombocyte hyperactivation in diabetic nephropathies]. Tóth L; Szénási P; Varsányi-Nagy M; Szilvási I; Lehoczky E; Németh C; Kammerer L; Romics L Orv Hetil; 1991 May; 132(21):1135-8, 1141. PubMed ID: 1828563 [TBL] [Abstract][Full Text] [Related]
6. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy. Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142 [TBL] [Abstract][Full Text] [Related]
7. [Cytokines in noninvasive diagnostics of diabetic nephropathy progression]. Senatorski G; Paczek L; Kropiewnicka E; Bartłomiejczyk I Pol Merkur Lekarski; 2002 Nov; 13 Suppl 1():28-32. PubMed ID: 12621778 [TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor beta 1 and monocyte chemoattractant protein-1 as prognostic markers of diabetic nephropathy. Shaker OG; Sadik NA Hum Exp Toxicol; 2013 Oct; 32(10):1089-96. PubMed ID: 23515495 [TBL] [Abstract][Full Text] [Related]
9. Role of tissue inhibitors of metalloproteinase in diabetic nephropathy. Kanauchi M; Nishioka H; Nakashima Y; Hashimoto T; Dohi K Nihon Jinzo Gakkai Shi; 1996 Mar; 38(3):124-8. PubMed ID: 8721333 [TBL] [Abstract][Full Text] [Related]
10. [Serum beta 2-microglobulin as a index of the initiation of dialysis therapy for diabetic patients with chronic renal failure]. Nakamura Y; Yasui A; Fukuda T; Yamamoto N; Ono T Nihon Jinzo Gakkai Shi; 1991 Oct; 33(10):983-7. PubMed ID: 1770630 [TBL] [Abstract][Full Text] [Related]
11. A study on nephropathy in type 2 diabetes mellitus: histology and its correlation with clinical and biochemical parameters. Bhattacharya S; Mandal SK; Bandyopadhyay R; Chakrabarti S; Basu AK; Pal S J Indian Med Assoc; 2007 Oct; 105(10):592, 594-6. PubMed ID: 18383954 [TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein H is increased in type 2 diabetic patients with microalbuminuria. Cavallo Perin P; Gruden G; Giunti S; Arnaldi L; Cassader M; Gambino R; Pagano G Nutr Metab Cardiovasc Dis; 2000 Dec; 10(6):311-4. PubMed ID: 11302005 [TBL] [Abstract][Full Text] [Related]
13. Advanced glycosylation end products in patients with diabetic nephropathy. Makita Z; Radoff S; Rayfield EJ; Yang Z; Skolnik E; Delaney V; Friedman EA; Cerami A; Vlassara H N Engl J Med; 1991 Sep; 325(12):836-42. PubMed ID: 1875967 [TBL] [Abstract][Full Text] [Related]
14. [Relationship between platelet hyperactivation and dyslipoproteinemia in diabetic nephropathy]. Tóth L; Szénási P; Varsányi-Nagy M; Szilvási I; Vörös P; Romics L; Kammerer L Orv Hetil; 1992 Apr; 133(17):1037-40. PubMed ID: 1579341 [TBL] [Abstract][Full Text] [Related]
15. Increased serum levels of interleukin-18 in patients with diabetic nephropathy. Mahmoud RA; el-Ezz SA; Hegazy AS Ital J Biochem; 2004 Jul; 53(2):73-81. PubMed ID: 15646011 [TBL] [Abstract][Full Text] [Related]
16. Urinary beta 2-microglobulin levels and urinary N-acetyl-beta-D-glucosaminidase enzyme activities in early diagnosis of non-insulin-dependent diabetes mellitus nephropathy. Mocan Z; Erem C; Yildirim M; Telatar M; Değer O Diabetes Res; 1994; 26(3):101-7. PubMed ID: 7621616 [TBL] [Abstract][Full Text] [Related]
17. Serum cystatin C in diabetic patients. Not only an indicator for renal dysfunction in patients with overt nephropathy but also a predictor for cardiovascular events in patients without nephropathy. Ogawa Y; Goto T; Tamasawa N; Matsui J; Tando Y; Sugimoto K; Tomotsune K; Kimura M; Yasujima M; Suda T Diabetes Res Clin Pract; 2008 Feb; 79(2):357-61. PubMed ID: 17980929 [TBL] [Abstract][Full Text] [Related]
18. Biomarkers for early diagnosis of type 2 diabetic nephropathy: a study based on an integrated biomarker system. Huang M; Liang Q; Li P; Xia J; Wang Y; Hu P; Jiang Z; He Y; Pang L; Han L; Wang Y; Luo G Mol Biosyst; 2013 Aug; 9(8):2134-41. PubMed ID: 23719966 [TBL] [Abstract][Full Text] [Related]
19. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Shimoike T; Inoguchi T; Umeda F; Nawata H; Kawano K; Ochi H Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022 [TBL] [Abstract][Full Text] [Related]
20. Comparison of urinary excretion of albumin, alpha 1-microglobulin and retinol-binding protein in diabetic patients. Galanti LM; Jamart J; Dell'omo J; Donckier J Diabetes Metab; 1996 Oct; 22(5):324-30. PubMed ID: 8896994 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]